{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T13:17:17Z","timestamp":1784639837133,"version":"3.55.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1268,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder, characterized by significant long-term cardiac involvement. Dilated cardiomyopathy (DCM) is the main cause of death in DMD, and angiotensin-converting enzyme inhibitors (ACEi) and beta-blockers (BB) are first-line treatments in DCM. It is unknown whether angiotensin receptor-neprilysin inhibitor (ARNi) could provide greater benefits in this setting. Our aim is to assess whether ARNi use may prevent deterioration in ejection fraction (EF) or is associated with EF improvement compared with ACEi in DMD patients with heart failure and to report the tolerability of ARNi in this group of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We followed 22 DMD patients, 6 of them with an EF &amp;lt; 40% and 16 with an EF &amp;gt; 40%. The first group received ARNi on top of BB, while the control group started or continued first-line therapy with ACEi \u00b1 BB. From December 2016 to December 2021, we recorded EF values at baseline and at follow-up, comparing EF changes. Median follow-up was 7 months (interquartile range 4.7\u20139.1). At baseline, the mean of EF (%) in the ARNi group was 31 \u00b1 2%, while it was 59 \u00b1 9% in the control group. At follow-up, we recorded an EF improvement in the ARNi group (38 \u00b1 6%, P-value &amp;lt; 0.05). Among controls, EF at follow-up was substantially unchanged from baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data suggest that the use of ARNi in DMD patients with DCM and an EF &amp;lt; 40% might be associated with an EF improvement and a safe tolerability profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13963","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T02:50:13Z","timestamp":1655434213000},"page":"3639-3642","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Angiotensin Receptor-Neprilysin Inhibitor in Symptomatic Patients with Duchenne Dilated Cardiomyopathy: A Primetime"],"prefix":"10.1093","volume":"9","author":[{"given":"Alessandra","family":"Arcudi","sequence":"first","affiliation":[{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Di Francesco","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Rodolico","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"D'Amario","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart , Rome ,","place":["Italy"]},{"name":"Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"2026012114152598200_ehf213963-bib-0001","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","article-title":"The pathogenesis and therapy of muscular dystrophies","volume":"16","author":"Guiraud","year":"2015","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"2026012114152598200_ehf213963-bib-0002","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/jcm7090291","article-title":"Dystrophin cardiomyopathies: clinical management, molecular pathogenesis and evolution towards precision medicine","volume":"7","author":"D'Amario","year":"2018","journal-title":"J Clin Med"},{"key":"2026012114152598200_ehf213963-bib-0003","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1136\/heartjnl-2017-311269","article-title":"A current approach to heart failure in Duchenne muscular dystrophy","volume":"103","author":"D'Amario","year":"2017","journal-title":"Heart"},{"key":"2026012114152598200_ehf213963-bib-0004","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.rehab.2013.06.002","article-title":"Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011","volume":"56","author":"Kieny","year":"2013","journal-title":"Ann Phys Rehabil Med"},{"key":"2026012114152598200_ehf213963-bib-0005","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012114152598200_ehf213963-bib-0006","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114152598200_ehf213963-bib-0007","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"2026012114152598200_ehf213963-bib-0008","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.chest.2020.04.043","article-title":"Cardiorespiratory progression over 5 years and role of corticosteroids in Duchenne muscular dystrophy: a single-site retrospective longitudinal study","volume":"158","author":"Trucco","year":"2020","journal-title":"Chest"},{"key":"2026012114152598200_ehf213963-bib-0009","article-title":"Current practices in treating cardiomyopathy and heart failure in Duchenne muscular dystrophy (DMD): understanding care practices in order to optimize DMD heart failure through ACTION","volume":"1-9","author":"Villa","year":"2022","journal-title":"Pediatr Cardiol"},{"key":"2026012114152598200_ehf213963-bib-0010","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ahj.2007.05.014","article-title":"Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up","volume":"154","author":"Duboc","year":"2007","journal-title":"Am Heart J"},{"key":"2026012114152598200_ehf213963-bib-0011","first-page":"136","article-title":"Beneficial effects of one-month sacubitril\/valsartan treatment in a patient affected by end-stage dystrophinopathic cardiomyopathy","volume":"39","author":"Papa","year":"2020","journal-title":"Acta Myol"},{"key":"2026012114152598200_ehf213963-bib-0012","article-title":"Cardiovascular disease in Duchenne muscular dystrophy: overview and insight into novel therapeutic targets","author":"Schultz","year":"2022","journal-title":"JACC: Basic Transl Sci"},{"key":"2026012114152598200_ehf213963-bib-0013","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.12998\/wjcc.v7.i23.4098","article-title":"Recurrent hypotension induced by sacubitril\/valsartan in cardiomyopathy secondary to Duchenne muscular dystrophy: a case report","volume":"7","author":"Li","year":"2019","journal-title":"World J Clin Cases"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13963","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13963","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/5\/3639\/65352378\/eschf_9_5_3639.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/5\/3639\/65352378\/eschf_9_5_3639.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:18:19Z","timestamp":1769023099000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/5\/3639\/8323008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":13,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,6,16]]},"published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13963","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10]]},"published":{"date-parts":[[2022,6,16]]},"assertion":[{"value":"2022-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}